Towards a science-based testing strategy to identify maternal thyroid hormone imbalance and neurodevelopmental effects in the progeny – part II: how can key events of relevant adverse outcome pathways be addressed in toxicological assessments?-Reference-Cited by-同舟云学术

Towards a science-based testing strategy to identify maternal thyroid hormone imbalance and neurodevelopmental effects in the progeny – part II: how can key events of relevant adverse outcome pathways be addressed in toxicological assessments?

Published:2021-04-21 Issue:4 Volume:51 Page:328-358
ISSN:1040-8444
Container-title:Critical Reviews in Toxicology
language:en
Short-container-title:Critical Reviews in Toxicology

Author:

Marty Sue¹^ORCID,Beekhuijzen Manon²,Charlton Alex³,Hallmark Nina⁴^ORCID,Hannas Bethany R.⁵,Jacobi Sylvia⁶,Melching-Kollmuss Stephanie⁷,Sauer Ursula G.⁸,Sheets Larry P.⁹,Strauss Volker⁷^ORCID,Urbisch Daniel⁷,Botham Philip A.³,van Ravenzwaay Bennard⁷^ORCID

Affiliation:

1. The Dow Chemical Company, Midland, MI, USA

2. Charles River Laboratories, Den Bosch, The Netherlands

3. Syngenta, Jealott’s Hill, Bracknell, United Kingdom

4. Bayer AG, Monheim, Germany

5. Corteva Agriscience, Newark, DE, USA

6. Albemarle, Louvain-la-Neuve, Belgium

7. BASF SE, Ludwigshafen, Germany

8. Scientific Consultancy – Animal Welfare, Neubiberg, Germany

9. Bayer Crop Science, Chesterfield, MO, USA

Publisher

Informa UK Limited